Trinity Biotech (TRIB) PT Lowered to $20 at Roth Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq drops as tech megacap declines outweigh upbeat chip outlook
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
Trinity Biotech Announces Quarter 2 Financial Results Enrolment for the Meritas Troponin ACS Study Now Completed
July 28, 2015 9:29 AM EDTDUBLIN, July 28, 2015 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended June 30, 2015.
Quarter 2 Results                                                                                          Total revenues for Q2, 2015 were $24.3m compared to $26.0m in Q2, 2014. However, when the impact of foreign exchange movements, due to the strength of the US dollar against a range of other currencies, is removed, revenues would have been $25.4m this quarter, thus representing a decrease of 2%.Â
Point-of-Care revenues for Q2, 2015 were $3.4m, which represents a decrease of... More
